Press Release title Fredun Pharmaceuticals Delivers Robust FY 26 Performance; Revenue Jumps 40%, EBITDA Surges 72% and Profit Rises ~60% YoY
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Fredun Pharmaceuticals reported strong FY26 results with total income rising 40% YoY to ₹639 crore. EBITDA jumped 72% to ₹95 crore with margins expanding 276 basis points to 14.83%. Net profit grew ~60% to ₹33 crore, outpacing revenue growth and indicating improving business quality. The company also announced a ₹0.70 per share dividend and proposed a 2:1 bonus share issuance. Management highlighted diversification across generics, nutraceuticals, cosmeceuticals, and pet care, along with new launches in hormone therapy and the DAULCÉL wellness platform. Credit rating was upgraded to IVR BBB+ stable.
The results demonstrate strong operational performance with profitability growing faster than revenue, reflecting operating leverage and cost discipline. The bonus issue and dividend signal confidence in future prospects and could positively impact investor sentiment.